CYP2A6 rs412852: Nicotine Metabolism and Traits
The rs412852 variant is a single nucleotide polymorphism located in or near the CYP2A6 gene on chromosome 19. The CYP2A6 enzyme serves as the primary pathway for metabolizing nicotine into inactive cotinine in the liver. Research associates genetic variation at this locus with differences in nicotine clearance rates and daily cigarette consumption patterns.
What each genotype means
Typical nicotine metabolism
This genotype represents the most common form of the CYP2A6 gene in many populations. Research suggests individuals with this profile typically exhibit standard rates of nicotine metabolism, though individual smoking behaviors are influenced by many complex genetic and environmental factors. Please discuss any concerns regarding nicotine metabolism or smoking cessation strategies with your clinician or pharmacist.
This is the most common genotype observed across most global populations.
Varied nicotine metabolism
Carrying one copy of the variant allele may be associated with subtle differences in how your body processes nicotine compared to those with two copies of the common allele. Because the evidence linking this specific variant to clinical outcomes is limited, it is unclear how this genotype influences your personal nicotine metabolism rate. Please consult with a healthcare professional if you have questions about how your genetics might relate to smoking cessation or nicotine intake.
This genotype is found in a significant portion of the population, with frequencies varying by ancestry.
Potential altered nicotine metabolism
Individuals with this genotype carry two copies of the variant allele, which has been studied for its potential association with altered nicotine metabolism rates. While some research suggests a link between CYP2A6 variation and cigarette consumption patterns, the evidence remains limited and inconsistent across different groups. You should discuss any health-related questions or smoking cessation plans with your doctor or a qualified pharmacist.
This genotype is less common than the heterozygous state and its prevalence varies significantly across different global ancestral groups.
Genetic Location and Overview of rs412852
The single nucleotide polymorphism rs412852 is positioned on chromosome 19 within the cytochrome P450 gene cluster, specifically mapping to the CYP2A6 locus. Human chromosomes harbor diverse forms of variation, and single nucleotide polymorphisms (SNPs) represent single base substitutions that can alter gene expression, splicing, or protein stability. In the human genome, CYP2A6 is part of a complex genomic region that includes closely related pseudogenes and paralogs such as CYP2A7 and CYP2A13. Because this cluster exhibits high sequence homology, variants within or flanking CYP2A6 often tag broader haplotypes or structural variations. The rs412852 variant typically presents with two common alleles, C and T (with corresponding genomic strand designations depending on the assembly). Cataloged as a trait-associated marker rather than a primary monogenic disease mutation, rs412852 is primarily evaluated for its statistical relationship with physiological metabolic rates and behavioral phenotypes.
The Biological Role of the CYP2A6 Enzyme
The CYP2A6 gene encodes cytochrome P450 family 2 subfamily A member 6, a major hepatic enzyme responsible for the biotransformation of numerous endogenous and xenobiotic compounds. Most notably, CYP2A6 accounts for up to 70 to 80 percent of the initial metabolic clearance of nicotine, converting it via C-oxidation into the inactive metabolite cotinine. Beyond nicotine, the enzyme contributes to the metabolic processing of pharmaceutical agents such as halothane, disulfiram, and valproic acid, as well as the bioactivation of certain environmental pro-carcinogens like tobacco-specific nitrosamines. The rate at which an individual's liver metabolizes nicotine directly influences how long nicotine remains active in the central nervous system. When nicotine is cleared rapidly, individuals often experience shorter durations of neurochemical reward, which can reinforce more frequent consumption. Conversely, reduced CYP2A6 enzymatic activity leads to slower nicotine breakdown and prolonged systemic exposure.
Research Findings and Strength of Evidence
Genome-wide association studies (GWAS) and candidate gene analyses have repeatedly implicated the CYP2A6 locus in variation surrounding the nicotine metabolite ratio (NMR), plasma cotinine concentrations, and total cigarettes smoked per day. However, the specific evidence directly attributing a functional consequence exclusively to rs412852 is characterized as limited. In many association studies, rs412852 functions as an indirect proxy or linked tag SNP that reflects larger haplotypic patterns or functional star alleles across the CYP2A6 region. While the biological link between CYP2A6 activity and smoking behaviors is robustly demonstrated across diverse research cohorts, individual common SNPs like rs412852 typically explain only a modest fraction of the total phenotypic variance. Furthermore, effect sizes can fluctuate depending on ancestral background, linkage disequilibrium architecture, and environmental factors such as concurrent medication use or daily stress levels.
Population Frequency and Ancestral Diversity
The rs412852 variant is widely distributed across human populations, exhibiting minor allele frequencies that typically range between 0.35 and 0.45 across broad, multi-ancestry cohorts cataloged in public resources like gnomAD and dbSNP. Because both alleles are common globally, a substantial proportion of individuals across European, African, Asian, and Admixed American groups carry at least one copy of the minor allele. However, the broader genetic architecture of the CYP2A6 locus is recognized for substantial ethnic diversity. For example, specific reduced-function and null alleles—such as CYP2A6*2, CYP2A6*4, CYP2A6*7, and CYP2A6*9—display markedly different baseline frequencies in East Asian, African, and European populations. Consequently, the correlation between rs412852 and actual metabolic rates may vary between demographic groups depending on the presence of these background functional variants.
Practical Implications and Medical Context
Understanding your rs412852 genotype provides educational insight into the physiological factors that help shape drug metabolism and nicotine processing in population-level studies. However, direct-to-consumer genetic findings for this marker cannot diagnose nicotine dependence, predict individual smoking habits with certainty, or serve as a standalone diagnostic tool. Smoking behaviors and addiction risk are complex, multifactorial traits governed by dozens of genetic loci, psychological stressors, socioeconomic factors, and personal choices. In addition, CYP2A6 variation influences certain pharmaceutical pathways; however, personal genetic test results must never be used to initiate, alter, or discontinue any prescription medication. If you have questions about smoking cessation strategies or how your body handles specific medications, consult a qualified physician or clinical pharmacist for evidence-based guidance.
How common is this variant?
The minor allele frequency for rs412852 generally ranges from approximately 0.35 to 0.45 across diverse global cohorts in gnomAD, making heterozygous and homozygous genotypes common across most ancestral populations.
Frequently asked questions
Does having a specific rs412852 genotype make me addicted to smoking?
No. The rs412852 variant does not cause addiction. While CYP2A6 influences how quickly nicotine is cleared from the bloodstream, addiction is an intricate outcome shaped by multiple genes, environment, mental health, and individual behavioral choices.
Can rs412852 determine how quickly my liver processes nicotine?
The variant rs412852 is statistically associated with nicotine metabolism rates in research cohorts, but individual metabolic capacity depends on overall CYP2A6 haplotypes, copy number variations, and liver health. A single variant provides only limited insight into total enzyme activity.
Can I use this genetic result to pick a smoking cessation treatment?
No, you should not select or alter smoking cessation therapies based solely on rs412852. While pharmacogenetic studies investigate how nicotine clearance affects response to nicotine replacement therapy or non-nicotine medications, treatment plans must always be coordinated with a healthcare provider.
How common is the rs412852 variant in the general population?
The rs412852 variant is very common globally. Data from large databases such as gnomAD show that the minor allele frequency falls roughly between 35% and 45%, meaning a substantial portion of the world's population carries one or two copies.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs412852?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2A6
Functional splice-site variant defining CYP2A6*20 associated with significantly reduced enzyme activity and slower nicotine and coumarin clearance.
Defining functional variant for the CYP2A6*2 allele (L160H) causing defective nicotine C-oxidation and slower metabolic nicotine clearance.
Defines the non-functional CYP2A6*2 allele (p.Leu160His) conferring absent nicotine C-oxidation activity and slow nicotine metabolism.
Functional variant in CYP2A6 defining the *9 allele with decreased transcriptional activity and reduced rate of nicotine metabolism.
Functional polymorphism defining the CYP2A6*9 reduced-function promoter variant causing slower nicotine and cotinine metabolism.
Defining coding polymorphism for CYP2A6*8 (p.Arg365Gln), resulting in significantly decreased catalytic activity towards substrate medications including tegafur.